NervGen Pharma: Phase 3 study started recruiting, 150 planned (Chronic Spinal Cord Injury)
NervGen Pharma: Phase 3 study started recruiting, 150 planned (Chronic Spinal Cord Injury). Its enrollment of 150 is above the median of 80 (71st percentile). Dated 2 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 150 · 71th percentile of 8,879 ClinicalTrialStartPulse records · 1.9x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | NervGen Pharma |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury |
| NCT ID | NCT07799532 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Chronic Spinal Cord Injury |
| Intervention types | drug |
| Target enrollment | 150 |
| Site countries | United States, Canada |
| Posted | 2026-09-02 |
| Planned start | 2026-09-28 |
| Event | Started recruiting |
| Event date | 2026-09-28 |
| Last update posted | 2026-11-03 |
| enrollment percentile | 71th of 8,879 (median 80, 1.9x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch NervGen Pharma
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of US records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock NervGen Pharma + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-03
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: NervGen Pharma and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- NervGen Pharma's enrollment: 71st percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 150 participants planned.
What is the ClinicalTrialStartPulse record for NervGen Pharma?
NervGen Pharma's Phase 3 study (NCT07799532) in Chronic Spinal Cord Injury, first posted 2026-09-02: started recruiting (2026-09-28), in an update posted 2026-11-03.
How does NervGen Pharma compare to other ClinicalTrialStartPulse records?
Its enrollment of 150 sits in the upper half (71th percentile) of 8,879 records; the median is 80. It is fresh: dated 2 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
NervGen Pharma vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
| AstraZeneca | US | 181 | 74th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor NervGen Pharma and peer phase 3 records
Get new ClinicalTrialStartPulse records like NervGen Pharma by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.